Gain Therapeutics, Inc.

GANX Healthcare Biotechnology

Gain Therapeutics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $55,200.00, down 60.6% from fiscal 2022. In the quarter to June 2026, EPS grew 42.1%, free cash flow grew 8.22% and total debt fell 23.9%, each against the same quarter a year earlier.

1.26 0.07 −5.26%
Market cap
$58.1M
P/E
0.0×
Fwd P/E
−2.4×
Dividend yield
—
F-score
1/9
Altman Z
−1.79
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

— — — —
EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
2.52 6.63 4.69 4.36
Net Debt/EBITDA
1.76 4.61 3.03 2.74
Debt/Equity
0.07 0.02 0.03 0.03
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(0.14) (0.14) (0.11) (0.11)
Book value per Share
0.17 0.56 0.33 0.26
Free Cash Flow
(4.93) (4.62) (4.73) (4.68)
Other line items

Show all line items

Columns are period end dates